Latest On HOOKIPA Pharma Inc (HOOK):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-05-11 20:40 EST | News | HOOKIPA Pharma GAAP EPS of -$0.27 misses by $0.03, revenue of $3.17M misses by $1.34M | N/A |  |
| 2023-04-26 18:30 EST | News | Hookipa gains on upcoming presentation on cancer drug | N/A | |
| 2023-04-18 23:49 EST | News | Hookipa Pharma: A Speculative Biotech Worthy Of A Spot On My Watch List | N/A | |
| 2023-03-16 03:34 EST | News | HOOKIPA Pharma Inc. (HOOK) Q4 2022 Earnings Call Transcript | N/A | |
| 2023-03-15 12:14 EST | News | HOOKIPA Pharma GAAP EPS of -$0.17 beats by $0.04, revenue of $7.83M beats by $4.56M | N/A | |
About HOOKIPA Pharma Inc (HOOK):
HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immune-therapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase II clinical trial in patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop infectious disease product candidates intended to support functional cures for chronic Hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in read more... 2011 and is headquartered in New York, New York.
General
- Name HOOKIPA Pharma Inc
- Symbol HOOK
- Type Common Stock
- Exchange NASDAQ
- Currency USD
- Country USA
- SectorHealthcare
- IndustryBiotechnology
- Full Time Employees 85
- Fiscal Year EndDecember
- IPO Date2019-04-18
- Gic SectorHealth Care
- Gic GroupPharmaceuticals, Biotechnology & Life Sciences
- Gic IndustryBiotechnology
- Web URLhttp://www.hookipapharma.com
Valuation
- Price/Sales (Trailing 12 Mt.) 16.81
- Price/Book (Most Recent Quarter) 3.8
- Enterprise Value Revenue 15.45
Financials
- Most Recent Quarter 2020-09-30
- Next Quarter EPS Estimate -$0.47
- Profit Margin -232%
- Operating Margin -284%
- Return on Assets -23%
- Return on Equity -38%
- Revenue 18.04 million
- Earnings Per Share -$4.91
- Revenue Per Share $0.7
- Gross Profit -34370000
- Quarterly Earnings Growth 98.2%
Highlights
- Market Capitalization 391.05 million
- EBITDA -30286000
- PE Ratio -1.04
- Analyst Target Price $22.29
- Book Value Per Share $3.59
Share Statistics
- Shares Outstanding 25.76 million
- Shares Float 14.38 million
- % Held by Insiders 1132%
- % Held by Institutions 47.29%
- Shares Short 1.29 million
- Shares Short Prior Month 1.3 million
- Short Ratio 8.3
- Short % of Float 7%
- Short % of Shares Outstanding 4%
Technicals
- 52 Week High $13.7
- 52 Week Low $7.07
- 50 Day Moving Average 11.85
- 200 Day Moving Average 11
Dividends
- Dividend Date N/A
- ExDividend Date N/A
- Dividend Yield 0%
HOOKIPA Pharma Inc (HOOK) Dividend Calendar:
HOOKIPA Pharma Inc (HOOK) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
HOOKIPA Pharma Inc (HOOK) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date |
|---|
| Research Development |
| Income Before Tax |
| Selling General Administrative |
| Gross Profit |
| Ebit |
| Operating Income |
| Income Tax Expense |
| Total Revenue |
| Cost of Revenue |
| Total Other Income Expense Net |
| Net Income From Continuing Operations |
| Net Income Applicable to Common Shares |
Cash Flow:
| Date |
|---|
| Investments |
| Change to Liabilities |
| Total Cash Flow from Investing Activities |
| Net Borrowings |
| Total Cash Flow from Financial Activities |
| Change to Operating Activities |
| Change in Cash |
| Total Cash from Operating Activities |
| Depreciation |
| Other Cash Flow from Investing Activities |
| Change to Inventory |
| Change to Account Receivables |
| Other Cash Flow from Financing Activities |
| Change to Net Income |
| Capital Expenditures |
Balance Sheet:
| Date |
|---|
| Total Liabailities |
| Total Stockholder Equity |
| Other Current Liabilities |
| Total Assets |
| Common Stock |
| Other Current Assets |
| Retained Earnings |
| Other Liabilities |
| Other Assets |
| Cash |
| Total Current Liabilities |
| Other Stockholder Equity |
| Property, Plant & Equipment |
| Total Current Assets |
| Long Term Investments |
| Net Tangible Assets |
| Short Term Investments |
| Long Term Debt |
| Inventory |
| Accounts Payable |
HOOKIPA Pharma Inc (HOOK) Chart:
HOOKIPA Pharma Inc (HOOK) News:
Below you will find a list of latest news for HOOKIPA Pharma Inc (HOOK) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
HOOKIPA Pharma Inc (HOOK) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
Latest HOOK Trades:
HOOKIPA Pharma Inc (HOOK) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | View |
|---|---|---|
| 2020-10-23 | 3 (Initial statement of beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-23 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-10-19 | 8-K (Current report) | |
| 2020-10-06 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-09-17 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-08-13 | 8-K (Current report) | |
| 2020-08-13 | 10-Q (Quarterly report [Sections 13 or 15(d)]) | |
| 2020-07-24 | 4/A (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
| 2020-07-22 | 4 (Statement of changes in beneficial ownership of securities) | |
HOOKIPA Pharma Inc (HOOK) Insider Transactions:
Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of HOOKIPA Pharma Inc (HOOK). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1132%
Institutional Ownership: 4729%
| Transaction Date | Insider Name | Insider Title | Type | Shares Number | Shares Price | Total Transaction | Shares Held After Transaction | Link |
|---|---|---|---|---|---|---|---|---|
| 2020-10-21 | Deventer Sander van | Director | Buy | 2,485.00 | 2,485.00 | | ||
| 2020-10-21 | David Ross Kaufman | Director | Buy | 4,577.00 | 4,577.00 | | ||
| 2020-10-21 | Christoph Lengauer | Director | Buy | 4,603.00 | 4,603.00 | | ||
| 2020-10-21 | Graziano Seghezzi | Director | Buy | 4,708.00 | 4,708.00 | | ||
| 2020-10-21 | Julie O'Neill | Director | Buy | 4,969.00 | 4,969.00 | | ||
| 2020-10-21 | Michael Aaron Kelly | Director | Buy | 5,754.00 | 5,754.00 | | ||
| 2020-10-21 | de Winkel Jan van | Director | Buy | 9,153.00 | 9,153.00 | | ||
| 2020-10-02 | CAPITAL VI FCPR SOFINNOVA | 10% Share Holder | Sell | 300.00 | 10.00 | 3,000.00 | 3,906,194.00 | |
| 2020-09-15 | CAPITAL VI FCPR SOFINNOVA | 10% Share Holder | Sell | 9,261.00 | 13.16 | 121,912.73 | 3,906,494.00 | |
| 2020-09-15 | CAPITAL VI FCPR SOFINNOVA | 10% Share Holder | Sell | 32,336.00 | 12.45 | 402,563.80 | 3,915,755.00 | |
| 2020-07-20 | Klaus Orlinger | EVP, Research | Buy | 1,216.00 | 1,216.00 | | ||
| 2020-07-20 | Roman Necina | Chief Technology Officer | Buy | 1,984.00 | 1,984.00 | | ||
| 2020-07-20 | Reinhard Kandera | Chief Financial Officer | Buy | 2,036.00 | 2,036.00 | | ||
| 2020-07-20 | CAPITAL VI FCPR SOFINNOVA | 10% Share Holder | Sell | 12,483.00 | 11.94 | 149,101.95 | 3,948,091.00 | |
| 2020-07-20 | Jorn Aldag | Chief Executive Officer | Buy | 4,128.00 | 4,128.00 | | ||
| 2020-07-20 | Igor Matushansky | Chief Medical Officer | Buy | 2,736.00 | 56,134.00 | | ||
| 2020-06-29 | CAPITAL VI FCPR SOFINNOVA | 10% Share Holder | Sell | 3,280.00 | 11.78 | 38,627.58 | 3,960,574.00 | |
| 2020-01-29 | Igor Matushansky | Chief Medical Officer | Sell | 5,500.00 | 12.73 | 69,992.45 | 53,398.00 | |
| 2020-01-23 | Anders Lilja | Sr. VP, Technical Development | Sell | 4,075.00 | 12.17 | 49,601.31 | 0.00 | |
| 2020-01-23 | Anders Lilja | Sr. VP, Technical Development | Sell | 7,568.00 | 12.81 | 96,931.70 | 0.00 | |